Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access
View original at finance.yahoo.comNovo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access New, lower list price of $675 per month across Wegovy®, Ozempic®, and Rybelsus®, effective January 1, 2027, addresses access barriers to our innovati…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
With the supply of all doses of these medicines fully available nationwide in the US, there is no reason for patients to gamble with their health with knock-off products produced by compounders
80% confidenceNot all GLP-1s are the same. Semaglutide offers powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with a broad range of indications
80% confidenceThe lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs
80% confidenceThis change does not impact other access efforts, including direct-to-patient, self-pay prices
80% confidenceLowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States
80% confidence
Data points we hold from this source
| Novo Nordisk · employee count us | 10000 employees |
| Novo Nordisk · employee count | 68800 employees |
| Novo Nordisk · countries operating | 80 countries |
| Novo Nordisk · countries marketing | 170 countries |